Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GB-5267 - IV only, GB-5267- only, GB-5267 -Combined IV and IP Infusion, GB-5267-Combined and IP Infusion
GB-5267 · 1 trial · 1 indication
Determine the MTD by assessing the incidence of dose limiting toxicities (DLTs) of GB-5267
Evaluated using the Clopper-Pearson method
| Arm | Type | Description |
|---|---|---|
| IV Only | EXPERIMENTAL | Patients receive IV only infusion of GB-5267 cells |
| Dose Expansion with Combined IV and IP Infusion | EXPERIMENTAL | A combined administration of both IV and IP infusions. |
| Name | Type | Description |
|---|---|---|
| GB-5267 - IV only | BIOLOGICAL | IV infusion |
| GB-5267 -Combined IV and IP Infusion | BIOLOGICAL | IV and IP Infusion |
Inclusion Criteria: * At least 18 years of age * Patients must have epithelial ovarian, peritoneal, or fallopian tube cancer that is confirmed by histology or cytology, with a histopathological diagnosis of serous, clear cell, endometrioid, mucinous carcinoma, or carcinosarcoma. * Must have platinu...
GB-5267 is an investigational monoclonal antibody being developed for the treatment of platinum-resistant ovarian cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
GB-5267 targets MUC16, a protein associated with ovarian cancer. By binding to MUC16, the antibody is designed to interfere with tumor cell activity, though the exact mechanism is still under investigation in clinical trials.
GB-5267 is being developed by Generate Biomedicines, Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and efficacy in patients with platinum-resistant ovarian cancer.
GB-5267 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its safety and effectiveness.
GB-5267 is being studied in a Phase 1 clinical trial with the identifier NCT07489287. This trial is designed to evaluate the drug in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer and is not yet recruiting participants.
Yes, GB-5267 is also known as GB-5267 - IV only, indicating that the drug is administered intravenously. This alternative name is used in clinical trial documentation to specify the route of administration.